by GlobeNewsWire | Jul 13, 2016 | Globe Newswire
JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) — Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis Limited, a life sciences company focused on the...
by GlobeNewsWire | Jul 13, 2016 | Globe Newswire
TORONTO, July 13, 2016 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic...
by GlobeNewsWire | Jul 13, 2016 | Globe Newswire
BEDMINSTER, N.J., July 13, 2016 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and...
by GlobeNewsWire | Jul 13, 2016 | Globe Newswire
NEW YORK and LONDON, July 13, 2016 (GLOBE NEWSWIRE) — Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a...
by GlobeNewsWire | Jul 13, 2016 | Globe Newswire
Q4 Net sales of $93.4 million, up 3% year-over-yearQ4 GAAP loss per share of $1.21, inclusive of a one-time tax asset write down of $40.1 million; Non-GAAP adjusted EPS of $0.19, up 37% year-over-yearQ4 Operating cash generation of $18.5 millionFY2017 revenue guidance...